C
Christian Junghanss
Researcher at University of Rostock
Publications - 175
Citations - 3011
Christian Junghanss is an academic researcher from University of Rostock. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 20, co-authored 144 publications receiving 2514 citations.
Papers
More filters
Journal ArticleDOI
Characterization of the novel indolylmaleimides' PDA-66 and PDA-377 effect on canine lymphoma cells.
Wen Liu,Julia Beck,Laura C. Schmidt,Catrin Roolf,Anahit Pews-Davtyan,Barbara C. Rütgen,Sabine E. Hammer,Saskia Willenbrock,Anett Sekora,Arndt Rolfs,Matthias Beller,Bertram Brenig,Ingo Nolte,Christian Junghanss,Ekkehard Schütz,Hugo Murua Escobar +15 more
TL;DR: Both PDA derivatives displayed strong anti-proliferation activity in canine B-cell lymphoma cells, and expression analyses indicated that the drug acting mechanism is mediated through DNA replication and cycle arrest involving the spindle assembly checkpoint.
Journal ArticleDOI
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Catrin Roolf,Nikolaj Dybowski,Anett Sekora,Stefan Mueller,Gudrun Knuebel,Andreas Tebbe,Hugo Murua Escobar,Klaus Godl,Christian Junghanss,Christoph Schaab +9 more
TL;DR: The data suggest that the FLT3 status in AML patients might not be the only factor predicting response to treatment with sorafenib, and the affected pathways differed in sorAFenib sensitive FLT 3-ITD− andFLT3- ITD+ cells.
Journal ArticleDOI
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.
Volker Schmidt,Dietger Niederwieser,Thomas Schenk,Gerhard Behre,Anne Klink,Christian Pfrepper,Axel Hinke,Dietrich W. Beelen,Christian Junghanss,Lutz Uharek,William Krüger,Andreas Hochhaus,Herbert G. Sayer +12 more
TL;DR: The results from a prospective, controlled multicenter trial designed to evaluate efficacy and safety of palifermin for prevention of oral mucositis in TBI-based allogeneic HSCT are reported.
Journal ArticleDOI
Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia.
Anna Richter,Elisabeth Fischer,Clemens Holz,Julia Schulze,Sandra Lange,Anett Sekora,Gudrun Knuebel,Larissa Henze,Catrin Roolf,Hugo Murua Escobar,Christian Junghanss +10 more
TL;DR: In this paper, the effect of pan-AKTK/AKT inhibitors on B-ALL cell lines and primary samples and investigate potential synergistic effects with BCL-2 inhibitor venetoclax to overcome limitations in apoptosis induction.
Journal ArticleDOI
Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study
Dietger Niederwieser,Verena S. Hoffmann,Markus Pfirrmann,Haifa Kathrin Al-Ali,Sebastian Schwind,Vladan Vucinic,Rainer Krahl,Christoph Kahl,Hans-Heinrich Wolf,Ute Kreibich,Detlef Hähling,Ute Hegenbart,Carsten Hirt,Norma Peter,Axel Florschuetz,Kolja Reifenrath,Antje Schulze,Niklas Zojer,Sebastian Scholl,Christian Junghanss,Wolfram Pönisch,Simone Heyn,Herbert G. Sayer,Andreas Hochhaus,Thomas Heinicke,Thomas Fischer,Alwin Krämer,Peter Dreger,Georg Maschmeyer,Utz Krug,Maria C. Sauerland,Achim Heinecke,Rüdiger Hehlmann,Eva Lengfelder,Wolfgang Hiddemann,Hubert Serve,Carsten Müller-Tidow,Wolfgang E. Berdel,Thomas Büchner +38 more
TL;DR: A prospective randomized trial was designed among German AML study groups with different treatment strategies to compare outcome, finding no differences with respect to cytogenetic risk groups, white blood cell counts, LDH, and npm1 mutant/ flt3-wildtype or mutant.